Overview

• The new test, called ROBIN, uses nanopore sequencing to deliver brain tumour diagnoses within two hours of surgery, compared to the traditional six to eight weeks.
• In a trial involving 50 surgeries, the test achieved a 100% success rate in providing rapid diagnostic results and detailed tumour classifications.
• The technology consolidates multiple genetic tests into one, reducing costs to approximately £450 per patient, with potential for further savings at scale.
• Researchers are collaborating with NHS Trusts to integrate the test nationally, aiming to improve patient care and equity of access across the UK.
• Experts highlight the test's potential to reduce patient anxiety, accelerate treatment timelines, and inform surgical strategies in real-time.